Cerebral Palsy Clinical Trial
— XARAOfficial title:
Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy
Verified date | July 2020 |
Source | Merz Pharmaceuticals GmbH |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of one or both arms alone or in combination with injections into one or both legs are effective and safe in treating children/adolescents (age 2-17 years) with increased muscle tension/uncontrollable muscle stiffness (spasticity) due to cerebral palsy.
Status | Completed |
Enrollment | 351 |
Est. completion date | August 28, 2018 |
Est. primary completion date | July 4, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 17 Years |
Eligibility | Inclusion Criteria: - Female or male subject of 2 to 17 years of age (inclusive). - Uni- or bilateral Cerebral Palsy (CP) with clinical need for injections with NT 201 for the treatment of upper limb (UL) spasticity at least unilaterally. - Ashworth Scale (AS) score in the main clinical target patterns in this study: 1. Flexed elbow: AS=2 in elbow flexors (at least unilaterally). and/or 2. Flexed Wrist: AS=2 in wrist flexors (at least unilaterally). - Clinical need according to the judgment of the investigator in one out of five treatment combinations (A-E, as shown below). AS score must be =2 for each target pattern chosen for injection at the Baseline Injection Visit V2. A. UL(s) treatment only (GMFCS I-V): A1) Unilateral treatment of UL spasticity with 8 U/kg BW NT 201 (maximum of 200 U) for: 1. At least one of the main clinical target patterns flexed elbow (4 U/kg BW) and/or flexed wrist (2 U/kg BW). and 2. Additional clinical patterns in the same limb (i.e., clenched fist, thumb in palm, and/or pronated forearm) with the remaining units until maximum dose of 8 U/kg BW (maximum of 200 U) for treatment of a single UL is reached. or A2) Bilateral treatment of UL spasticity with equal doses of 8 U/kg BW NT 201 (maximum of 200 U) to each UL. Dose per UL must be distributed between: 1. At least one of the main clinical target patterns flexed elbow (4 U/kg BW) and/or flexed wrist (2 U/kg BW). and 2. Additional clinical patterns in the same limb (i.e., clenched fist, thumb in palm, and/or pronated forearm) with the remaining units until maximum dose of 8 U/kg BW (maximum of 200 U) for treatment of a single UL is reached. B. Unilateral UL and unilateral lower limb (LL) treatment (GMFCS I-V): B1) Unilateral treatment of UL spasticity with 8 U/kg BW NT 201 (maximum of 200 U) for: 1. At least one of the main clinical target patterns flexed elbow (4 U/kg BW) and/or flexed wrist (2 U/kg BW). and 2. Additional clinical patterns in the same limb (i.e., clenched fist, thumb in palm, and/or pronated forearm) with the remaining units until maximum dose of 8 U/kg BW (maximum of 200 U) for treatment of a single UL is reached. plus B2) Ipsilateral unilateral treatment of LL spasticity with 8 U/kg BW NT 201 (maximum of 200 U). Dose to LL must be distributed to at least one of clinical target patterns pes equinus, flexed knee, adducted thigh, and extended great toe as clinically needed. C. Unilateral UL and bilateral LL treatment (GMFCS I-III) C1) Unilateral treatment of UL spasticity with 8 U/kg BW NT 201 (maximum of 200 U) for: 1. At least one of the main clinical target patterns flexed elbow (4 U/kg BW) and/or flexed wrist (2 U/kg BW). and 2. Additional clinical patterns in the same limb (i.e., clenched fist, thumb in palm, and/or pronated forearm) with the remaining units until maximum dose of 8 U/kg BW (maximum of 200 U) for treatment of a single UL is reached. plus C2) Bilateral treatment of LL spasticity with 12 U/kg BW (maximum of 300 U). Dose must be distributed into at least one of clinical target patterns pes equinus, flexed knee, adducted thigh, and extended great toe, on each side. Dose distribution may vary between sides as clinically needed. D. Unilateral UL and bilateral LL treatment (GMFCS IV and V) D1) Unilateral treatment of UL spasticity with 8 U/kg BW NT 201 (maximum of 200 U) for: 1. At least one of the main clinical target patterns flexed elbow (4 U/kg BW) and/or flexed wrist (2 U/kg BW). and 2. Additional clinical patterns in the same limb (i.e., clenched fist, thumb in palm, and/or pronated forearm) with the remaining units until maximum dose of 8 U/kg BW (maximum of 200 U) for treatment of a single UL is reached. plus D2) Bilateral treatment of LL spasticity with 8 U/kg BW (maximum of 200 U). Dose must be distributed into at least one of clinical target patterns pes equinus, flexed knee, adducted thigh, and extended great toe, on each side. Dose distribution may vary between sides as clinically needed. E. Bilateral UL treatment and bilateral LL treatment (GMFCS I-III) E1) Bilateral treatment of UL spasticity with equal doses of 8 U/kg BW NT 201 (maximum of 200 U) to each UL. Dose per UL must be distributed between 1. At least one of the main clinical target patterns flexed elbow (4 U/kg BW) and/or flexed wrist (2 U/kg BW) and 2. Additional clinical patterns in the same limb (i.e., clenched fist, thumb in palm, and/or pronated forearm) with the remaining units until maximum dose of 8 U/kg BW (maximum of 200 U) for treatment of a single UL is reached. plus E2) Bilateral treatment of LL spasticity with 4 U/kg BW (maximum of 100 U). Dose must be distributed into at least one of clinical target patterns pes equinus, flexed knee, adducted thigh, and extended great toe, on each side. Dose distribution may vary between sides as clinically needed. Exclusion Criteria: Pre-treated (non-naïve) subjects must not have received BoNT treatment within the last 14 weeks prior to Screening Visit (V1) in any indication. |
Country | Name | City | State |
---|---|---|---|
Argentina | Merz Investigational Site #054005 | Caba | |
Argentina | Merz Investigational Site #054010 | Godoy Cruz | Provincia De Mendoza |
Mexico | Merz Investigational Site #052023 | Aguascalientes | |
Mexico | Merz Investigational Site #052003 | Guadalajara | |
Mexico | Merz Investigational Site #052022 | Mexico City | |
Mexico | Merz Investigational Site #052024 | Mexico City | |
Mexico | Merz Investigational Site #052027 | Monterrey | |
Mexico | Merz Investigational Site #052028 | Monterrey | |
Mexico | Merz Investigational Site #052026 | Zapopan | |
Poland | Merz Investigational Site #048089 | Bialystok | |
Poland | Merz Investigational Site #048063 | Gdansk | |
Poland | Merz Investigational Site #048059 | Krakow | |
Poland | Merz Investigational Site #048084 | Lublin | |
Poland | Merz Investigational Site #048094 | Poznan | |
Poland | Merz Investigational Site #048075 | Sandomierz | |
Poland | Merz Investigational Site #048060 | Wiazowna | |
Russian Federation | Merz Investigational Site #007014 | Kazan | |
Russian Federation | Merz Investigational Site #007015 | Khabarovsk | |
Russian Federation | Merz Investigational Site #007018 | Novosibirsk | |
Russian Federation | Merz Investigational Site #007298 | Saint Petersburg | |
Russian Federation | Merz Investigational Site #007013 | Smolensk | |
Russian Federation | Merz Investigational Site #007019 | Stavropol | |
Ukraine | Merz Investigational Site #380001 | Dnipropetrovsk | |
Ukraine | Merz Investigational Site #380005 | Kharkiv | |
Ukraine | Merz Investigational Site #380002 | Kyiv | |
Ukraine | Merz Investigational Site #380003 | Odessa | |
United States | Merz Investigational Site #001186 | Chicago | Illinois |
United States | Merz Investigational Site #001283 | Columbia | Missouri |
United States | Merz Investigational Site #001286 | Gulf Breeze | Florida |
United States | Merz Investigational Site #001284 | Loxahatchee Groves | Florida |
United States | Merz Investigational Site No. #001302 | Royal Oak | Michigan |
United States | Merz Investigational Site #001285 | Savannah | Georgia |
Lead Sponsor | Collaborator |
---|---|
Merz Pharmaceuticals GmbH |
United States, Argentina, Mexico, Poland, Russian Federation, Ukraine,
Dabrowski E, Chambers HG, Gaebler-Spira D, Banach M, Kanovský P, Dersch H, Althaus M, Geister TL, Heinen F. IncobotulinumtoxinA Efficacy/Safety in Upper-Limb Spasticity in Pediatric Cerebral Palsy: Randomized Controlled Trial. Pediatr Neurol. 2021 May 21; — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | MP: Change From Baseline in Ashworth Scale (AS) in UL Primary Clinical Target Pattern at Week 4 | The AS categorizes severity of spasticity by judging resistance to passive movement. Spasticity was assessed by using the 5-point AS with:0 (no increase in tone); 1 (slight increase in tone giving a "catch" when the limb was moved in flexion or extension); 2 (more marked increase in tone, but limb easily flexed); 3 (considerable increase in tone -passive movements difficult); 4 (limb rigid in flexion or extension). Values represent least square (LS) mean differences between baseline and Week 4 resulting from Mixed Model Repeated Measurement (MMRM) models comparing high versus low and in a second step mid versus low dose groups, respectively. Values for the low group may differ slightly depending on the comparison and are therefore provided separately for each comparison. | Baseline and Week 4 | |
Primary | Co-primary Variable MP: Investigator's Global Impression of Change Scale (GICS) at Week 4 | The GICS was used to measure independently the investigator's impression of change due to treatment. The response option was a common 7-point Likert scale, that ranges from +3 (very much improved); +2 (much improved); +1 (minimally improved); 0 (no change); -1 (minimally worse); -2 (much worse); -3 (very much worse). Values represent LS mean differences between baseline and Week 4 resulting from ANCOVA models comparing high versus low and in a second step mid versus low dose groups, respectively. Values for the low group may differ slightly depending on the comparison and are therefore provided separately for each comparison. | Week 4 | |
Secondary | MP: Change From Baseline in AS Score of the Other Treated UL Main Clinical Target Pattern at Week 4 | The AS categorizes the severity of spasticity by judging resistance to passive movement. Spasticity was assessed by 5-point scale at visits, where: 0 (no increase in tone); 1(slight increase in tone giving a "catch" when the limb was moved in flexion or extension); 2(more marked increase in tone, but limb easily flexed); 3(considerable increase in tone - passive movements difficult); 4(limb rigid in flexion or extension). Values represent LS mean differences between baseline and Week 4 resulting from MMRM models comparing high versus low and in a second step mid versus low dose groups, respectively. Values for the low group may differ slightly depending on the comparison and are therefore provided separately for each comparison. | Baseline and Week 4 | |
Secondary | MP: Change From Baseline in AS Score in UL Treated Clenched Fist With Flexed Wrist at Week 4 | The AS categorizes the severity of spasticity by judging resistance to passive movement. Spasticity was assessed by 5-point scale at visits, where: 0 (no increase in tone); 1(slight increase in tone giving a "catch" when the limb was moved in flexion or extension); 2(more marked increase in tone, but limb easily flexed); 3(considerable increase in tone - passive movements difficult); 4(limb rigid in flexion or extension). Values represent LS mean differences between baseline and Week 4 resulting from MMRM models comparing high versus low and in a second step mid versus low dose groups, respectively. Values for the low group may differ slightly depending on the comparison and are therefore provided separately for each comparison. | Baseline and Week 4 | |
Secondary | MP: Change From Baseline in AS Score for Each Treated Clinical Pattern of the UL at Week 4 | The AS categorizes the severity of spasticity by judging resistance to passive movement. Spasticity was assessed by 5-point scale at visits, where: 0 (no increase in tone); 1(slight increase in tone giving a "catch" when the limb was moved in flexion or extension); 2(more marked increase in tone, but limb easily flexed); 3(considerable increase in tone - passive movements difficult); 4(limb rigid in flexion or extension). Values represent LS mean differences between baseline and Week 4 resulting from MMRM models comparing high versus low and in a second step mid versus low dose groups, respectively. Values for the low group may differ slightly depending on the comparison and are therefore provided separately for each comparison. | Baseline up to Week 4 | |
Secondary | MP: Change From Baseline in Scores of Pain Intensity (From Participants) and Pain Frequency (From Parent/Caregiver) Assessed With 'Questionnaire on Pain Caused by Spasticity (QPS)' | Pain intensity (from participants) and pain frequency (from parent/caregiver) to be assessed with QPS. The QPS Total Score for pain intensity ranges from 0 ('No Hurt') to 10 ('Hurt Worst'). The QPS Total Score for the observed pain frequency ranges from 0 (Never) to 4 (Always). Values represent LS mean differences between baseline and Week 4 resulting from MMRM models comparing high versus low and in a second step mid versus low dose groups, respectively. Values for the low group may differ slightly depending on the comparison and are therefore provided separately for each comparison. P/C = Parent/Caregiver. | Baseline, Weeks 4, 8, and 14 | |
Secondary | MP: Child's/Adolescent's, and Parent's/Caregiver's GICS in UL at Week 4 | The GICS was used to measure independently the child's/adolescent's, and parent's or caregiver's impression of change due to treatment. The response option was a common 7-point Likert scale, that ranges from: +3(very much improved); +2(much improved); +1(minimally improved); 0(no change); -1(minimally worse); -2(much worse); -3(very much worse). Values represent LS mean differences between baseline and Week 4 resulting from ANCOVA models comparing high versus low and in a second step mid versus low dose groups, respectively. Values for the low group may differ slightly depending on the comparison and are therefore provided separately for each comparison. | Week 4 | |
Secondary | Number of Participants With Occurrence of Treatment Emergent Adverse Events (TEAEs) Overall and Per Treatment Cycle | Baseline up to Week 66 | ||
Secondary | Number of Participants With Occurrence of TEAEs of Special Interest (TEAESIs) Overall and Per Treatment Cycle | Baseline up to Week 66 | ||
Secondary | Number of Participants With Occurrence of Serious TEAEs (TESAEs) Overall and Per Treatment Cycle | Baseline up to Week 66 | ||
Secondary | Number of Participants With Occurrence of TEAEs Related to Treatment Overall and Per Treatment Cycle | Baseline up to Week 66 | ||
Secondary | Number of Participants With Occurrence of TEAEs by Worst Intensity Overall and Per Treatment Cycle | Baseline up to Week 66 | ||
Secondary | Number of Participants With Occurrence of TEAEs by Worst Causal Relationship Overall and Per Treatment Cycle | Baseline up to Week 66 | ||
Secondary | Number of Participants With Occurrence of TEAEs by Final Outcome Overall and Per Treatment Cycle | Baseline up to Week 66 | ||
Secondary | Number of Participants With Occurrence of TEAEs Leading to Discontinuation Overall and Per Treatment Cycle | Baseline up to Week 66 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05317234 -
Genetic Predisposition in Cerebral Palsy
|
N/A | |
Recruiting |
NCT05576948 -
Natural History of Cerebral Palsy Prospective Study
|
||
Completed |
NCT04119063 -
Evaluating Wearable Robotic Assistance on Gait
|
Early Phase 1 | |
Completed |
NCT03264339 -
The Small Step Program - Early Intervention for Children With High Risk of Developing Cerebral Palsy
|
N/A | |
Completed |
NCT05551364 -
Usability and Effectiveness of the ATLAS2030 Exoskeleton in Children With Cerebral Palsy
|
N/A | |
Completed |
NCT03902886 -
Independent Walking Onset of Children With Cerebral Palsy
|
||
Recruiting |
NCT05571033 -
Operant Conditioning of the Soleus Stretch Reflex in Adults With Cerebral Palsy
|
N/A | |
Not yet recruiting |
NCT04081675 -
Compliance in Children With Cerebral Palsy Supplied With AFOs
|
||
Completed |
NCT02167022 -
Intense Physiotherapies to Improve Function in Young Children With Cerebral Palsy
|
N/A | |
Completed |
NCT04012125 -
The Effect of Flexible Thoracolumbar Brace on Scoliosis in Cerebral Palsy
|
N/A | |
Enrolling by invitation |
NCT05619211 -
Piloting Movement-to-Music With Arm-based Sprint-Intensity Interval Training Among Children With Physical Disabilities
|
Phase 1 | |
Completed |
NCT04489498 -
Comparison of Somatometric Characteristics Between Cerebral Palsy and Normal Children, Cross-sectional, Multi Center Study
|
||
Completed |
NCT03677193 -
Biofeedback-enhanced Interactive Computer-play for Youth With Cerebral Palsy
|
N/A | |
Recruiting |
NCT06450158 -
Robot-assisted Training in Children With CP
|
N/A | |
Completed |
NCT04093180 -
Intensive Neurorehabilitation for Cerebral Palsy
|
N/A | |
Completed |
NCT02909127 -
The Pediatric Eating Assessment Tool
|
||
Not yet recruiting |
NCT06377982 -
Human Umbilical Cord Blood Infusion in Patients With Cerebral Palsy
|
Phase 1 | |
Not yet recruiting |
NCT06007885 -
Examining Capacity Building of Youth With Physical Disabilities to Pursue Participation Following the PREP Intervention.
|
N/A | |
Not yet recruiting |
NCT03183427 -
Corpus Callosum Size in Patients With Pineal Cyst
|
N/A | |
Active, not recruiting |
NCT03078621 -
Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Cerebral Palsy
|
Phase 1/Phase 2 |